NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Rheumatoid Arthritis
Date of first enrollment	21/05/2010
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : LY2439821 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : LY2439821 30, 80, 180 mg or placebo is administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10. For final cohort, LY2439821 120 mg at Weeks 0, 240mg at Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 or placebo is administered subcutaneously at Weeks 0, 1, 2, 3, 4, 5, 6, 7, 8 ,9 and 10.

Outcome(s)

Primary Outcome
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	<= 75age old
Gender	Both
Include criteria	Eligible patients are those who have rheumatoid arthritis according to the American Rheumatism Association 1987 revised criteria, who have used methotrexate for at least 12 weeks and have been on a stable dose, at least 7.5 mg/week, for no less than 8 weeks. Serum C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) values must be more than the upper limit of normal (ULN) at study entry.
Exclude criteria